Login to Your Account


Panel: Shift focus to manufacturing as cell therapies near market

By Nuala Moran
Staff Writer

Thursday, November 3, 2016

LONDON – A number of cell-based cancer immunotherapies are months from being filed with regulators, but, in the rush to prove safety and efficacy, manufacturing issues have been overlooked.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription